Skip to main content
. 2022 Mar 29;12:860313. doi: 10.3389/fonc.2022.860313

Figure 1.

Figure 1

(A) The incidence rates and associations of HER2 alterations in NSCLC. Cohort A, B and C represent HER2 mutation, amplification and overexpression, respectively. Cohort C includes patients with IHC 2+ and 3+. (B) The underlying mechanisms of TKIs, ADCs and immune checkpoint inhibitors to cope with HER2-altered NSCLC.